Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | CuttingEdgeInfo Reports | Outcomes-Based Pharmaceutical Pricing (PH116)

Outcomes-Based Pharmaceutical Pricing (PH116)

Optimize pricing planning to satisfy customer group needs:

The pricing landscape has changed dramatically over the past decade. In the 1990s and even a few years ago, pricing was almost an afterthought — pricing plans were formed and carried out during ramp-up to product launch; there was less regulatory scrutiny; the concept of health outcomes analysis was still taking shape, and any pharmacoeconomic data that companies were able to provide was better than none.

Today, however, strategic pricing is more important than ever before. Pharmaceutical and biotechnology companies' pricing teams contend with unrelenting pressures. They must manage increased scrutiny from different sides — government agencies, the media and the public — over pharmaceutical pricing, while meeting multiple stakeholders' needs: third-party payers, physicians and patients. Adding to the complexity are ever-rising clinical development costs and shrinking pipelines in a constantly changing, global marketplace.

As a result of these challenges, pharmaceutical pricing has become payer-driven and value-based. But life sciences companies are also recognizing the vital importance of strategic pricing. Rather than coming at the tail end of a drug's development, pricing planning is being integrated into drug development. The pricing department, in fact, is now a key driver in lifecycle management.

Outcomes-Based Pharmaceutical Pricing: Meeting Stakeholder Needs examines these industry trends. It provides action items to resolve pricing departments' most pressing problems. Above all, it shows how forward-thinking companies maximize profits by addressing customers' preferences and ensuring that they set the right prices for their products. Use the report to:

* Maximize pricing departments' strategic capabilities

* Improve pricing decision making

* Streamline the pricing process

* Coordinate pricing and launch sequence strategies

* Improve cross-functional communication and involvement in pricing plans

* Benchmark pricing department resources

Report Metrics

Outcomes-Based Pharmaceutical Pricing's three chapters contain process, structure and resource data collected from 30 pharmaceutical and biotechnology companies. Key metrics include the following:

* Share of companies that have a dedicated department dedicated to driving pricing strategy — also broken down by company size

* Internal stakeholders that influence pricing efforts

* Cross-functional involvement in strategic pricing decisions

* Number of pricing studies conducted by phase, innovative versus me-too drugs

* Pricing staff support by phase of development, innovative versus me-too drugs

* Top criteria for determining product price: share of companies that rated each as most important

* Share of companies whose revenues have been eroded by parallel trade and re-importation

* Phase of development at which companies begin pricing research

* Effectiveness rating for pricing study types from 1 to 5

* Lifecycle entry and exit points for various functions involved in pricing

* Budget breakdown, by region and by company size

* 2008 pricing department headcount, by company size

* 2008 average headcount, by territory

* Global 2008 pricing budgets, by company size

* Groups that contribute funding to pricing

* Share of pricing budget that goes toward overhead expenses

* Expense ranges for a typical pricing study, by company size

Published 2008, 124 Pages, 400+ Metrics, 50+ Charts and Diagrams, Format: PDF
Table of Contents
Price: $7,695.00 / €5,143.34

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions